Author

Franck-Olivier Le Brun

EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN’S DISEASE: RESULTS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DIVERSITY1 STUDY
EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN’S DISEASE: RESULTS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DIVERSITY1 STUDY

Franck-Olivier Le Brun  et al.

SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES
SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES

Franck-Olivier Le Brun  et al.

Item 1 - 2 / 2
1